研究表明,临床上80%以上的肺癌为非小细胞肺癌(NSCLC),其中约1/2为肺腺癌,其余为鳞癌、大细胞癌等,患者就诊时多为晚期(ⅢB～Ⅳ期),只能接受化疗或姑息治疗。大量临床研究证实,以铂类为基础的联合化疗可显著延长晚期NSCLC患者的生存期,改善其生活质量[1]。为探讨抗代谢类抗癌药培美曲塞(PEM)联合顺铂(DDP)与多西他赛联 Studies have shown that more than 80% of lung cancer clinically non-small cell lung cancer (NSCLC), of which about 1/2 of lung adenocarcinoma, the rest of squamous cell carcinoma, large cell carcinoma, etc., when patients are mostly late treatment (ⅢB ~ Ⅳ ), Can only accept chemotherapy or palliative treatment. A large number of clinical studies have confirmed that platinum-based combination chemotherapy can significantly prolong the survival of patients with advanced NSCLC and improve their quality of life [1]. To investigate the anti-metabolic anticancer pemetrexed (PEM) combined with cisplatin (DDP) and docetaxel